Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RPA1 | P27694 | 4/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426056 | 0.86 | NOTUM (0.65) | NOTUMRPA1 | |
| SCHEMBL27591324 | 0.83 | MAP4K4 (0.61) | NOTUMMAP4K4NPC1RAB9AALDH1A1 | |
| SCHEMBL10414274 | 0.82 | KDM2B (0.47) | NOTUMMAP4K4LMNAHTT | |
| SCHEMBL4432842 | 0.81 | NOTUM (0.74) | NOTUMRAB9ARPA1ALDH1A1MAPT | |
| SCHEMBL30582339 | 0.79 | NOTUM (0.47) | NOTUMMAP4K4 | |
| SCHEMBL9826202 | 0.78 | NOTUM (1.00) | NOTUMNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL21688854 | 0.76 | NOTUM (0.44) | NOTUMMAP4K4NPC1RAB9AALDH1A1 | |
| SCHEMBL21639408 | 0.76 | NPC1 (0.47) | NOTUMMAP4K4NPC1RAB9AMAPT | |
| SCHEMBL30582312 | 0.76 | MAP4K4 (0.43) | NOTUMMAP4K4NPC1RAB9AALDH1A1 | |
| SCHEMBL3426673 | 0.76 | NOTUM (0.52) | NOTUMMAP4K4ABL1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358165-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-6683097-B2 | AFFINITY TO NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR SUBTYPE SELECTIVE BLOCKERS; MEDIATING PROCESSES UNDERLYING DEVELOPMENT OF CENTRAL NERVOUS SYSTEM AS WELL AS LEARNING AND MEMORY FORMATION | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| EP-1358165-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | NOTUM 4364/4885MAP4K4 602/4885NPC1 933/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | NOTUM 4107/4885MAP4K4 369/4885NPC1 1381/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | NOTUM 4107/4885MAP4K4 369/4885NPC1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.